Certain Rheumatoid Arthritis Meds May Help Lower Alzheimer’s Risk


By Alan Mozes
HealthDay Reporter

TUESDAY, April 12, 2022 (HealthDay Information) — Of their seek for a drug to prevent Alzheimer’s disease, scientists are looking at sure rheumatoid arthritis medication.

Preliminary findings recommend {that a} kind of rheumatoid arthritis drug referred to as TNF inhibitors could decrease dementia danger in rheumatoid arthritis sufferers who additionally undergo from coronary heart illness.

However nobody is suggesting these medication be prescribed broadly to stave off Alzheimer’s illness. The examine outcomes “ought to be merely thought-about hypothesis-generating,” harassed examine lead writer Rishi Desai. He is an assistant professor of drugs at Brigham and Girls’s Hospital and Harvard Medical Faculty in Boston.

As a substitute, Desai stated his group recommends “further research in numerous populations to analyze this commentary additional.”

The examine checked out dementia danger amongst greater than 22,500 older People who underwent remedy for rheumatoid arthritis in some unspecified time in the future between 2007 and 2017.

Examine contributors had been taking one in all three courses of rheumatoid arthritis remedy: JAK inhibitors (tofacitinib), IL-6 inhibitors (tocilizumab), or TNF inhibitors. All are designed to dam the kind of irritation that offers rise to debilitating rheumatoid arthritis symptoms.

In the long run, solely TNF medication have been discovered to be related to a decrease danger of creating dementia, and solely amongst these rheumatoid arthritis sufferers who additionally had coronary heart illness. The medication on this class embody Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab) and Cimzia (certolizumab pegol).

The report was printed on-line April 8 in JAMA Network Open.

“We have seen some hyperlinks between rheumatoid arthritis biology and Alzheimer’s biology, however these are advanced illnesses and we do not absolutely perceive the connections,” stated Heather Synder, vice chairman of medical and scientific relations with the Alzheimer’s Affiliation. The affiliation was not concerned within the present investigation.

“Whereas not essentially shocking, these new findings are fascinating and level to locations for future researchers to search for adjustments in dementia danger,” she added.

TNF stands for tumor necrosis issue, a protein that may set off inflammation and provides rise to immune system problems, akin to rheumatoid arthritis.

Its potential profit within the battle to scale back dementia danger was explored as a part of an initiative referred to as the Drug Repurposing for Efficient Alzheimer’s Medicines (DREAM) mission.

Sufferers included within the present evaluation have been aged 65 and up. Just below 20% have been being handled for rheumatoid arthritis with a JAK inhibitor, whereas a little bit greater than one-quarter have been receiving an IL-6 inhibitor remedy. The rest — a little bit over half — acquired a TNF inhibitor drug.

The researchers first got down to see how every of the three drug courses would possibly broadly affect dementia danger, as in contrast with a fourth rheumatoid arthritis remedy choice referred to as a T-cell activation inhibitor (abatacept). The group famous its personal prior analysis discovered that this fourth method provided no anti-dementia safety.

And this time round, the group additionally initially discovered no obvious connection between any of the three drug courses and a decrease danger for Alzheimer’s/dementia.

However a subsequent evaluation advised a decrease danger for dementia particularly amongst rheumatoid arthritis sufferers taking TNF medication who additionally had coronary heart illness. (About 13% of sufferers on TNF had a historical past of atrial fibrillation, nearly 15% had a historical past of coronary heart failure and roughly 9% had a historical past of stroke.)

As to what would possibly clarify the hyperlink, Desai stated coronary heart illness itself will increase the danger for creating dementia. However he stated the exact mechanism by which TNF would possibly decrease dementia danger in some sufferers stays unclear.

Snyder agreed.

“There may be not sufficient proof to recommend rheumatoid arthritis medicines are an efficient danger discount remedy for anybody inhabitants,” she stated. “Nonetheless, we encourage analysis on this area to proceed and people to contemplate taking part in Alzheimer’s clinical trials.”

Extra info

There’s extra on Alzheimer’s illness danger on the Alzheimer’s Affiliation.

SOURCES: Rishi J. Desai, MS, PhD, assistant professor, drugs, and affiliate epidemiologist, division of pharmaco-epidemiology and pharmaco-economics, division of drugs, Brigham and Girls’s Hospital and Harvard Medical Faculty, Boston; Heather Snyder, PhD, vice chairman, medical and scientific relations, Alzheimer’s Affiliation; JAMA Community Open, April 8, 2022, on-line


Please enter your comment!
Please enter your name here